Further progress in the treatment of multiple myeloma?
Malik
Prabhat Singh
PS
Department of Medical Oncology, Dr B.R. Ambedkar Institute of Rotary Cancer Hosptial, All India Institute of Medical Sciences, New Delhi
Kumar
Lalit
L
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D007194:India; D008558:Melphalan / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D011241:Prednisone / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D008558:Melphalan; D011241:Prednisone